Last updated on September 2018

A Phase 2a, Safety, Tolerability, Pharmacokinetics and Quantitative EEG Study of CX-8998 in Adolescents and Young Adults With Generalized Epileptic Syndromes With Absence Seizures


Brief description of study

This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4- dose-titration treatment period to dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.

 

Clinical Study Identifier: TX212730

Find a site near you

Start Over

University of South Florida-Morsani College of Medicine

2 Tampa General Circle Tampa, FL United States
  Connect »